⌘K
t
On 11 June 2024, N4 Pharma plc announced the publication of a new Corporate Presentation. This presentation is available for viewing on the Company's interactive investor hub.
| Date | 11 Jun 2024 |
| Time | 11:16:38 |
| Category | Miscellaneous |
| ID | 9877R |
N4 Pharma plc
("N4 Pharma" or the "Company")
New Corporate Presentation
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that a new Corporate Presentation has been published.
The Corporate Presentation can be viewed on the Company's interactive investor hub, at: https://investors.n4pharma.com/activity-updates/n4-pharma-company-presentation-june-24
For more information please contact:
|
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director |
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44(0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope |
Tel: +44(0)20 3657 0050 |
|
InvestorHub Engage with us by asking questions, watching video summaries and seeing what other shareholders have to say. |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.